On June 4, 2026 Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the "Company"), a biotech company focused on advancing cancer treatments, reported that it intends to close a registered direct offering with accredited investors for the purchase and sale of approximately $16.6 million of shares of Common Stock and pre-funded warrants at a price of (i) an offering price of $6.31 per share of common stock, and (ii) an offering price of $0.0001 per Pre-funded Warrant . The entire transaction was priced at the market under Nasdaq rules.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering consisted of the sale of 2,625,362 shares of common stock and Pre-Funded Warrant entitling the holder to purchase one share of common stock (and the common stock issuable from time to time upon exercise of such pre-funded warrants). The public offering price per common stock was $6.31 (or $6.3099 for each Pre-Funded Warrant, which was equal to the public offering price per common share sold in the offering minus an exercise price of $0.0001 per Pre-Funded Warrant). The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full.

Aggregate gross proceeds to the Company from the offering were approximately $16.6 million. The transaction closed on June 4, 2026. The Company intends to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.

Sichenzia Ross Ference Carmel LLP acted as counsel to the Company

The registered direct offering was made pursuant to an effective shelf registration statement on Form S-3 (No. 333-278874) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on May 2, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the offering have been filed with the SEC and are available on the SEC’s website located at www.sec.gov.

Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Lixte Biotechnology, JUN 4, 2026, View Source [SID1234666438])